Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment )- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Non-small Cell Lung Cancer Therapeutics Market Size, Report By 2033

The global non-small cell lung cancer therapeutics market size was valued at USD 19.85 billion in 2023 and is anticipated to reach around USD 66.20 billion by 2033, growing at a CAGR of 12.8% from 2024 to 2033.

Non-small Cell Lung Cancer Therapeutics Market Size, 2024 to 2033

Non-small Cell Lung Cancer Therapeutics Market Key Takeaways

  • The adenocarcinoma segment dominated the market in 2023 with a share of 43.13% in 2023
  • The squamous cell carcinoma (SCC) segment is anticipated to witness the fastest CAGR of 13.3% over the forecast period.
  • The targeted therapy segment dominated the market in 2023 with a share of 50.87% in 2023.
  • The immunotherapy segment is expected to grow at a significant CAGR over the forecast period.
  • The hospital pharmacy segment dominated the market in 2023 with a share of 66.17% in 2023.
  • The drug store and retail pharmacy segment is anticipated to witness a significant CAGR over the forecast period.
  • North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.77% in 2023.
  • Europe non-small cell lung cancer therapeutics market was identified as a lucrative region in this industry as it had a market share of 30.11% in 2023

The market growth is attributed to the increasing rate of patients being diagnosed with lungs disorders. Increased consumption of tobacco products, deteriorating air quality due to air pollution, and unhealthy lifestyle have also contributed to the increase in lung cancer. Furthermore, increased investments by major medical institutes for research and development of medicines and treatments related to the non-small cell lung cancer (NSCLC) have resulted in the growth of this market.

The increase in the number of patients suffering from lung cancer due to excessive smoking and use of other tobacco products has resulted in the market expansion. Furthermore, air pollution, passive smoking, and consumption of unsafe water has also increased the number of lung cancer patients. Furthermore, increased awareness spread by government and NGOs about tobacco consumptions and health complications caused due to it has increased the number of patients seeking diagnosis and treatment of their respiratory health.

Increased investments by major companies in research and development of medicines and therapies in order to treat NSCLC and other disorders have attributed in the market growth of this industry. Companies are targeting to increase the number of medicines approved by the regulatory bodies for the treatment of lung disorders. Furthermore, the rising use and demand for precision medicine, primarily driven by the development of targeted therapies that effectively target cancer cells has also resulted in the growth of this market.

U.S. Non-small Cell Lung Cancer Therapeutics Market Size, Industry Report, 2033

The U.S. non-small cell lung cancer therapeutics market size was valued at USD 4.97 billion in 2023 and is projected to surpass around USD 16.82  billion by 2033, registering a CAGR of 13.0% over the forecast period of 2024 to 2033.

U.S. Non-small Cell Lung Cancer Therapeutics Market Size, 2023 to 2033

North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.77% in 2023. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments. The market is also growing due to the presence of key market players who are targeting to deploy new and more effective medicines in order to treat NSCLC. Rise in the disposable income has increased the acceptance of costly treatments and drugs which further helps in the market growth of this region.

U.S. Non-small Cell Lung Cancer Therapeutics Market Trends

U.S. dominated themarket of North America in 2023 with a market share of 83.11% due to rise in the population with smoking addiction and air pollution. Presence of major medical institutes in the country helps in diagnosing the early stages of cancer. Major companies are investing heavily in the development of medicines and therapeutics, which is contributing to the market growth. Furthermore, growing awareness related to cancer treatment has increased the number of patients seeking diagnosis and treatment of their disorders.

Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 (%)

Europe Non-small Cell Lung Cancer Therapeutics Market Trends

Europe non-small cell lung cancer therapeutics market was identified as a lucrative region in this industry as it had a market share of 30.11% in 2023 due to presence of major medical institutes and increase in the population with smoking addiction. Furthermore, increased awareness about cancer treatment by the government and various NGOs has increased the number of patients seeking for the treatment of NSCLC. Therefore, these factors are responsible for the positive market growth in this region.

UK non-small cell lung cancer therapeutics market is expected to grow rapidly due to the increasing prevalence of cancer diseases and introduction of new drugs and therapies for the treatment of NSCLC. Rising awareness and early detection efforts have increased the diagnosis rates of various cancer disorders. Furthermore, increase in the drugs approved by the regulatory bodies has also helped in the market growth of NSCLC therapeutics in this country.

Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Trends

Asia Pacific had a significant market share in 2023 due to development in healthcare sector increasing population, and rising prevalence of NSCLC. Increase in the population with smoking addiction that are seeking medical help in order to diagnose and treat their lungs disorders has further resulted in the market growth in this region. Developing healthcare and deployment of new drugs in order to treat NSCLC has attributed in the increase in the diagnosis of patients with the disorders.

China non-small cell lung cancer therapeutics market held a substantial market share in non-small cell lung cancer therapeutics market due to increase in the adoption of therapies in order to treat NSCLC. With rise in the disposable income, adoption of costly therapies in order to treat NSCLC has increased. Furthermore, growing awareness of cancer treatments has resulted in the increase of patients seeking for treatments related to cancer.

Non-small Cell Lung Cancer Therapeutics Market Report Scope

Report Attribute Details
Market Size in 2024 USD 22.39 Billion
Market Size by 2033 USD 66.20 Billion
Growth Rate From 2024 to 2033 CAGR of 12.8%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Type, treatment, distribution channel, region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled F. Hoffmann-La Roche Ltd., Mylan N.V., Teva, Pharmaceutical Industries Ltd. , Sanofi , Pfizer Inc.,GSK plc , Novartis AG , Bayer AG , Eli Lilly and Company, Merck & Co., Inc.

Non-small Cell Lung Cancer Therapeutics Market By Type Insights

The adenocarcinoma segment dominated the market in 2023 with a share of 43.13% in 2023 due to increase in the population consuming tobacco and other products for smoking. Smoking addiction is one of the major reasons for patients diagnosed with adenocarcinoma. The segment is growing as the detection of adenocarcinoma is done at an early stage which allows for better treatment. Furthermore, increase in the targeted drugs used specifically to treat adenocarcinoma have further attributed to the market growth.

The squamous cell carcinoma (SCC) segment is anticipated to witness the fastest CAGR of 13.3% over the forecast period. This market growth is attributed to the rise in the patients exposed to UV radiation. SCC usually occurs in the neck and head region, including the nasal cavity, throat, lips and tongue regions. Furthermore, the awareness campaigns about SCC run by medical institutions and governments has led to more patients seeking treatment for the condition. Therefore, these factors are responsible for the market growth of this segment.

Non-small Cell Lung Cancer Therapeutics Market By Treatment Insights

The targeted therapy segment dominated the market in 2023 with a share of 50.87% in 2023. The factors responsible for the market growth are the benefits of this therapy such as increased number of targeted therapeutics and low percentage of side effects during the treatment. Targeted therapies are specifically used to disrupt cancer cell growth signals. Targeted therapies can be customized according to the patient type which helps in minimization of the side effects. Hence, these reasons are responsible for the upward market growth of this segment.

Non-small Cell Lung Cancer Therapeutics Market Share, By Treatment , 2023 (%)

The immunotherapy segment is expected to grow at a significant CAGR over the forecast period due to introduction of new products in the immunotherapy segment and increase in the preference of immunotherapy in order to treat cancer. Immunotherapy uses the immunity system in order to cure and control the cancer causing cells in the patient’s body. Furthermore, increased investments by key market players in order to develop better products to optimize the treatment has also helped in the market growth of this segment.

Non-small Cell Lung Cancer Therapeutics Market By Distribution Channel Insights

The hospital pharmacy segment dominated the market in 2023 with a share of 66.17% in 2023. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC. Increase in the number of medicines and  treatments available for treating NSCLC has further attributed in the market growth of segment as key market players are targeting to deploy more regulatory approved medicines in order to treat these  disorders. Therefore. These reasons are responsible for the market growth of hospital pharmacy segment.

The drug store and retail pharmacy segment is anticipated to witness a significant CAGR over the forecast period owing to the increased availability of regulatory approved drugs for consumption by patients seeking to cure NSCLC. Increased prevalence of lung cancer has resulted in the high demand for medications and treatments. Therefore, drug stores and retail pharmacies provides convenient access to medications. Furthermore, increased awareness about cancer treatment has resulted in the increase in number of patients seeking to consume medicines that helps in the treatment of lungs disorder. Therefore, these factors have resulted in the market growth of this segment.

Non-small Cell Lung Cancer Therapeutics Market Top Key Companies:

Some of the major companies in the non-small cell lung cancer therapeutics market are F.Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. Companies are focusing on deploying new drugs and therapies in order to deal with the rising demand for lung cancer patients.

  • Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with health care providers, governments and local communities to support and expand access to health care around the world.
  • F.Hoffmann-La Roche Ltd. Is a multinational healthcare company that operates in the pharmaceutical and diagnostics divisions. The company is a major provider of cancer treatments globally.

The following are the leading companies in the non-small cell lung cancer therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.

Non-small Cell Lung Cancer Therapeutics Market Recent Developments

  • In May 2024, Pfizer Inc. announced longer-term follow-up results from the phase 3 CROWN trial evaluating LORBRENA versus XALKORI for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After 5 years of median follow-up, there was an 81% reduction in the disease progression rate.
  • In March 2023, F.Hoffmann-La Roche Ltd. announced the approval of VENTANA PD-L1 (SP263) Assay as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients. The company believed that with this launch, more patients will have access to an additional immunotherapy option.

Non-small Cell Lung Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Non-small Cell Lung Cancer Therapeutics market.

By Type 

  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma
  • Others

By Treatment 

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Distribution Channel 

  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                        1.3.1. Information Procurement
                        1.3.2. Information or Data Analysis
                        1.3.3. Market Formulation & Data Visualization
                        1.3.4. Data Validation & Publishing
                    1.4. Research Scope and Assumptions
                        1.4.1. List of Data Sources
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope
                    3.1. Market Introduction/Lineage Outlook
                    3.2. Market Size and Growth Prospects (USD Million)
                    3.3. Market Dynamics
                        3.3.1. Market Drivers Analysis
                        3.3.2. Market Restraints Analysis
                    3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
                        3.4.1. Porter’s Analysis
                            3.4.1.1. Bargaining power of the suppliers
                            3.4.1.2. Bargaining power of the buyers
                            3.4.1.3. Threats of substitution
                            3.4.1.4. Threats from new entrants
                            3.4.1.5. Competitive rivalry
                        3.4.2. PESTEL Analysis
                            3.4.2.1. Political landscape
                            3.4.2.2. Economic and Social landscape
                            3.4.2.3. Technological landscape
                            3.4.2.4. Environmental landscape
                            3.4.2.5. Legal landscape
Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
                    4.3. Squamous Cell Carcinoma
                        4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.4. Large Cell Carcinoma
                    4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Adenocarcinoma
                        4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.7. Others
                        4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
                    5.3. Chemotherapy
                        5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.4. Targeted Therapy
                        5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Immunotherapy
                        5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
                    6.3. Hospital Pharmacy
                        6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.4. Drug Store and Retail Pharmacy
                        6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Online Pharmacy
                        6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis
                    7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 & 2030, USD Million
                    7.2. North America
                        7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.2.2. U.S.
                            7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.2.3. Canada
                            7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.2.4. Mexico
                            7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.3. Europe
                        7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.2. UK
                            7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.3. Germany
                            7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.4. France
                            7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.5. Italy
                            7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.6. Spain
                            7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.7. Denmark
                            7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.8. Sweden
                            7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.3.9. Norway
                            7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.4. Asia Pacific
                        7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.2. Japan
                            7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.3. China
                            7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.4. India
                            7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.5. Australia
                            7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.6. South Korea
                            7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.7. Thailand
                            7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Latin America
                        7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.2. Brazil
                            7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.3. Argentina
                            7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Middle East and Africa
                        7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.2. South Africa
                            7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.3. Saudi Arabia
                            7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.4. UAE
                            7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.5. Kuwait
                            7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis by Key Market Participants
                    8.2. Company Categorization
                    8.3. Company Heat Map Analysis
                    8.4. Company Profiles
                        8.4.1. F. Hoffmann-La Roche Ltd
                            8.4.1.1. Participant’s Overview
                            8.4.1.2. Financial Performance
                            8.4.1.3. Product Benchmarking
                            8.4.1.4. Recent Developments/ Strategic Initiatives
                        8.4.2. Mylan N.V.
                            8.4.2.1. Participant’s Overview
                            8.4.2.2. Financial Performance
                            8.4.2.3. Product Benchmarking
                            8.4.2.4. Recent Developments/ Strategic Initiatives
                        8.4.3. Teva Pharmaceutical Industries Ltd.
                            8.4.3.1. Participant’s Overview
                            8.4.3.2. Financial Performance
                            8.4.3.3. Product Benchmarking
                            8.4.3.4. Recent Developments/ Strategic Initiatives
                        8.4.4. Sanofi
                            8.4.4.1. Participant’s Overview
                            8.4.4.2. Financial Performance
                            8.4.4.3. Product Benchmarking
                            8.4.4.4. Recent Developments/ Strategic Initiatives
                        8.4.5. Pfizer Inc.
                            8.4.5.1. Participant’s Overview
                            8.4.5.2. Financial Performance
                            8.4.5.3. Product Benchmarking
                            8.4.5.4. Recent Developments/ Strategic Initiatives
                        8.4.6. GSK plc
                            8.4.6.1. Participant’s Overview
                            8.4.6.2. Financial Performance
                            8.4.6.3. Product Benchmarking
                            8.4.6.4. Recent Developments/ Strategic Initiatives
                        8.4.7. Novartis AG
                            8.4.7.1. Participant’s Overview
                            8.4.7.2. Financial Performance
                            8.4.7.3. Product Benchmarking
                            8.4.7.4. Recent Developments/ Strategic Initiatives
                        8.4.8. Bayer AG
                            8.4.8.1. Participant’s Overview
                            8.4.8.2. Financial Performance
                            8.4.8.3. Product Benchmarking
                            8.4.8.4. Recent Developments/ Strategic Initiatives
                        8.4.9. Eli Lilly and Company
                            8.4.9.1. Participant’s Overview
                            8.4.9.2. Financial Performance
                            8.4.9.3. Product Benchmarking
                            8.4.9.4. Recent Developments/ Strategic Initiatives
                        8.4.10. Merck & Co., Inc
                            8.4.10.1. Participant’s Overview
                            8.4.10.2. Financial Performance
                            8.4.10.3. Product Benchmarking
                            8.4.10.4. Recent Developments/ Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert